NEW YORK, April  29, 2026  (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) breached their

VTGN

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

Investigations into VTGN's Insider Conduct Could Impact Shareholder Value

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK, April  29, 2026  (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) breached their</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Kuehn Law is investigating potential fiduciary breaches by Vistagen Therapeutics&#039; insiders, alleging misrepresentation of clinical trial risks. The scrutiny could negatively affect VTGN&#039;s market reputation and stock performance, especially if legal outcomes arise.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kuehn Law is investigating potential fiduciary breaches by VTGN insiders.</li><li>VTGN reportedly misrepresented risks in clinical trials for Social Anxiety Disorder.</li><li>Concerns focus on Phase 2 trial data showing elevated placebo responses.</li><li>Shareholders are urged to participate before the deadline of April 1, 2024.</li><li>Legal actions could affect VTGN&#039;s reputation and share value.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Vistagen Therapeutics, Inc. (VTGN)</strong>: High scrutiny from legal investigations may impact VTGN’s market perception.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; as it addresses potential legal actions against company executives, impacting investor confidence and potentially leading to stock price fluctuations.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The investigation into VTGN&#039;s insiders may lead to significant stock price volatility.</li><li>Upcoming legal proceedings could deter investors and adversely impact share liquidity.</li><li>Failure to resolve legal issues could force management changes, affecting company stability.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Investigation initiated by Kuehn Law regarding VTGN&#039;s insider practices.</li><li>Shareholders who bought before April 1, 2024, are encouraged to participate.</li><li>Allegations relate to misrepresenting clinical trial risk for Social Anxiety Disorder.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider shorting VTGN given heightened legal scrutiny and potential share price decline.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>NEW YORK, April  29, 2026  (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of <strong><u>Vistagen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/VTGN">VTGN</a>)</u></strong> breached their fiduciary duties to shareholders.</p>  <p>According to a federal securities lawsuit, Insiders at Vistagen Therapeutics caused the company to misrepresent or fail to disclose the risk of failure inherent in public speaking challenge-based Social Anxiety Disorder clinical trials. Specifically, that from its own Phase 2 experience and published clinical research that public speaking challenge endpoints often exhibit elevated placebo responses, site variability and measurement noise, yet they continued to tout modifications made to the Phase 3 trial and presenting PALISADE-3 as likely to succeed.</p>  <p>If you currently own VTGN <strong>and purchased prior to April 01, 2024 </strong>please contact Justin Kuehn, Esq. by email at <a href="https://www.globenewswire.com/Tracker?data=EMA1uqWS4YyjbobCb_DG82Ly1tm6CeTar6fmBmM3vOl96FxkOXVKqLngOLawu5o9C-7C9xknpRDRev1bpaVdGwUCEGzMwIC-8akwtA95eQo=" rel="nofollow" target="_blank">justin@kuehn.law</a> or call (833) 672-0814. <strong>Kuehn Law pays all case costs and does not charge its investor clients.</strong> <em>Shareholders should contact the firm immediately as there may be limited time to enforce your rights.</em></p>  <p><strong>Why Your Participation Matters:</strong></p>  <p>As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. <em>Your investment. Your voice. Your future.</em>&#x2122;</p>  <p>For additional information, please visit <a href="https://www.globenewswire.com/Tracker?data=Fo1rhWJ747xrhI7QMeUpehSSx8tnKTPP2PlijONFPD82ho9DEGo09PyEUwPBjsuGEki9cXsFcl17_1vfM2qBq8G561gLOvYIu00Xl0vkr33yi3zVlyrRjsn-HxdsENQ1m6UfGMiIyCfSrh-pHMO-0AIS-2j3QFXMNNKyoEPKFS7MxnPSMyo5XYNfNMZI1ZOk" rel="nofollow" target="_blank">Shareholder Derivative Litigation - Kuehn Law</a>.</p>  <p>Attorney advertising. Prior results do not guarantee similar outcomes.</p>  <p>Contacts:<br></br>Kuehn Law, PLLC<br></br>Justin Kuehn, Esq.<br></br>53 Hill Street, Suite 605 <br></br>Southampton, NY 11968<br></br><a href="https://www.globenewswire.com/Tracker?data=EMA1uqWS4YyjbobCb_DG8x5mV1L1wtVBThK1ofUWLgbP-g5KwisG1NyJPl9LRq246-YhHWBODR-6-HisOrI8hSxoQQRqKyxBSXwbRow1CRI=" rel="nofollow" target="_blank">justin@kuehn.law</a><br></br>(833) 672-0814</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcwOTg0OSM3NTczOTkzIzIyODUyNTU="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MDFjODZmMTgtZjhiNy00OWZkLWEwZDItZjJiZDJhZDhlYjE5LTEyOTY4MDUtMjAyNi0wNC0yOS1lbg==/tiny/KUEHN-LAW-PLLC.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/83bde11e-8ae3-488a-a2c9-2ce956c44090"><img src="https://ml.globenewswire.com/media/83bde11e-8ae3-488a-a2c9-2ce956c44090/small/klaw-png.png" border="0" width="150" height="39" alt="Primary Logo"></img></a></p>

Kuehn Law is investigating potential fiduciary breaches by Vistagen Therapeutics' insiders, alleging misrepresentation of clinical trial risks. The scrutiny could negatively affect VTGN's market reputation and stock performance, especially if legal outcomes arise.

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News